Torcetrapib

• Catalog No.: PZ0170
• CAS Number: 262352-17-0
• M. F.: C26H25F9N2O4
• M. W.: 600.4733288
• Purity: ≥98% (HPLC)

SYNONYMS

• IUPAC name: ethyl (2R,4S)-4-({[3,5-bis(trifluoromethyl)phenyl]methyl}(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-1-carboxylate
• IUPAC Traditional name: torcetrapib
• Synonyms: CP-529414; CP-529,414; (2R,4S)-4-((3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester

DATABASE IDS

• CAS Number: 262352-17-0
• MDL Number: MFCD09260777

PROPERTIES

• Empirical Formula (Hill Notation): C26H25F9N2O4
• Purity: ≥98% (HPLC)
• Apperance: white powder
• Optical Rotation: [α]/D >-70°
• Solubility: DMSO: >5 mg/mL
• GHS Signal Word: Warning
• GHS Hazard statements: H302
• European Hazard Symbols: Harmful (Xn)
• Risk Statements: 22
• Storage Temperature: 2-8°C
• German water hazard class: 3

DETAILS

Description (English)

Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
Torcetrapib is a Cholesteryl ester transfer protein (CETP) inhibitor. CETP normally transfers cholesterol from HDL cholesterol to very low density or low density lipoproteins (VLDL or LDL). Inhibition of this process results in higher HDL levels (the "good" cholesterol-containing particle) and reduces LDL levels (the "bad" cholesterol). Unfortunately clinical trials were stopped because of excessive all cause mortality. Reasons are still being investigated, but may be related to some off target effects such as an increase in aldosterone secretion not found in some other CETP inhibitors.

Description (简体中文)

Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
Torcetrapib is a Cholesteryl ester transfer protein (CETP) inhibitor. CETP normally transfers cholesterol from HDL cholesterol to very low density or low density lipoproteins (VLDL or LDL). Inhibition of this process results in higher HDL levels (the "good" cholesterol-containing particle) and reduces LDL levels (the "bad" cholesterol). Unfortunately clinical trials were stopped because of excessive all cause mortality. Reasons are still being investigated, but may be related to some off target effects such as an increase in aldosterone secretion not found in some other CETP inhibitors.